Merck Reports P-III Trial (KEYNOTE-671) Results of Keytruda for Resectable Stage II, IIIA or IIIB Non-Small Cell Lung Cancer
Shots:
- The P-III trial evaluating neoadjuvant Keytruda (200mg, IV, q3w for up to four cycles) + CT in a ratio (1:1) in 786 patients with resectable stage II, IIIA or IIIB (T3-4N2) NSCLC
- The trial met its dual 1EPs of OS. At a pre-specified interim analysis, the results showed a significant & clinical improvement in OS over neoadjuvant PBO + CT, followed by adjuvant PBO & the safety profile was consistent with prior reported studies with no new safety signals
- The results will be presented at ESMO Congress 2023 and shared with regulatory authorities globally. At the first interim analysis, the trial met the dual primary EPs, EFS, as well as 2EPs of pCR & mPR, presented at ASCO 2023
Ref: Merck | Image: Merck
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
